PMID- 12388137 OWN - NLM STAT- MEDLINE DCOM- 20030110 LR - 20131121 IS - 0193-1849 (Print) IS - 0193-1849 (Linking) VI - 284 IP - 1 DP - 2003 Jan TI - Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. PG - E120-8 AB - To determine whether oxymetholone increases lean body mass (LBM) and skeletal muscle strength in older persons, 31 men 65-80 yr of age were randomized to placebo (group 1) or 50 mg (group 2) or 100 mg (group 3) daily for 12 wk. For the three groups, total LBM increased by 0.0 +/- 0.6, 3.3 +/- 1.2 (P < 0.001), and 4.2 +/- 2.4 kg (P < 0.001), respectively. Trunk fat decreased by 0.2 +/- 0.4, 1.7 +/- 1.0 (P = 0.018), and 2.2 +/- 0.9 kg (P = 0.005) in groups 1, 2, and 3, respectively. Relative increases in 1-repetition maximum (1-RM) strength for biaxial chest press of 8.2 +/- 9.2 and 13.9 +/- 8.1% in the two active treatment groups were significantly different from the change (-0.8 +/- 4.3%) for the placebo group (P < 0.03). For lat pull-down, 1-RM changed by -0.6 +/- 8.3, 8.8 +/- 15.1, and 18.4 +/- 21.0% for the groups, respectively (1-way ANOVA, P = 0.019). The pattern of changes among the groups for LBM and upper-body strength suggested that changes might be related to dose. Alanine aminotransferase increased by 72 +/- 67 U/l in group 3 (P < 0.001), and HDL-cholesterol decreased by -19 +/- 9 and -23 +/- 18 mg/dl in groups 2 and 3, respectively (P = 0.04 and P = 0.008). Thus oxymetholone improved LBM and maximal voluntary muscle strength and decreased fat mass in older men. FAU - Schroeder, E Todd AU - Schroeder ET AD - Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles 90033, USA. FAU - Singh, Atam AU - Singh A FAU - Bhasin, Shalender AU - Bhasin S FAU - Storer, Thomas W AU - Storer TW FAU - Azen, Colleen AU - Azen C FAU - Davidson, Tina AU - Davidson T FAU - Martinez, Carmen AU - Martinez C FAU - Sinha-Hikim, Indrani AU - Sinha-Hikim I FAU - Jaque, S Victoria AU - Jaque SV FAU - Terk, Michael AU - Terk M FAU - Sattler, Fred R AU - Sattler FR LA - eng GR - 1R01 AG-14369-01/AG/NIA NIH HHS/United States GR - 1R01 DK-49308-04/DK/NIDDK NIH HHS/United States GR - 1R01 DK-59627-01/DK/NIDDK NIH HHS/United States GR - 2R01 DK-49296-02A/DK/NIDDK NIH HHS/United States GR - G12 RR-03026/RR/NCRR NIH HHS/United States GR - M01 RR-430/RR/NCRR NIH HHS/United States GR - P20 RR-11145/RR/NCRR NIH HHS/United States GR - U01-DK-54047/DK/NIDDK NIH HHS/United States GR - U54 RR-14616/RR/NCRR NIH HHS/United States PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20020924 PL - United States TA - Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism JID - 100901226 RN - 0 (Anabolic Agents) RN - 0 (Blood Glucose) RN - 0 (Insulin) RN - 0 (Lipids) RN - 0 (Placebos) RN - 0 (Sex Hormone-Binding Globulin) RN - 3XMK78S47O (Testosterone) RN - 9002-67-9 (Luteinizing Hormone) RN - L76T0ZCA8K (Oxymetholone) SB - IM MH - Absorptiometry, Photon MH - Aged MH - Aged, 80 and over MH - Anabolic Agents/*administration & dosage MH - Biomechanical Phenomena MH - Blood Glucose/analysis MH - Body Composition/*drug effects MH - Double-Blind Method MH - Fasting MH - Humans MH - Insulin/blood MH - Lipids/blood MH - Luteinizing Hormone/blood MH - Male MH - Muscle, Skeletal/*drug effects/*physiology MH - Nutrition Assessment MH - Oxymetholone/*administration & dosage MH - Placebos MH - Sex Hormone-Binding Globulin/analysis MH - Testosterone/blood EDAT- 2002/10/22 04:00 MHDA- 2003/01/11 04:00 CRDT- 2002/10/22 04:00 PHST- 2002/10/22 04:00 [pubmed] PHST- 2003/01/11 04:00 [medline] PHST- 2002/10/22 04:00 [entrez] AID - 00363.2002 [pii] AID - 10.1152/ajpendo.00363.2002 [doi] PST - ppublish SO - Am J Physiol Endocrinol Metab. 2003 Jan;284(1):E120-8. doi: 10.1152/ajpendo.00363.2002. Epub 2002 Sep 24.